ACTIVExtend: 24 Months of Alendronate After 18 Months of Abaloparatide or Placebo for Postmenopausal Osteoporosis

Author(s):
Bone, H.G.; Cosman, F.; Miller, P.D.; Williams, G.C.; Hattersley, G.; Hu, M.Y.; Fitzpatrick, L.A.; Mitlak, B.; Papapoulos, S.; Rizzoli, R.; Dore, R.K.; Bilezikian, J.P.; Saag, K.G.
Published
2018
Publication type
Article / Letter to editor
Date issued
2018-08-31
Language
English
Is part of
Journal of Clinical Endocrinology and Metabolism (2018), Vol. 103, no. 8, p. 2949-2957
hdl
1887/86796
doi
10.1210/jc.2018-00163